Gain Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Gain Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 94% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 93% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -5%In 3 years sales changed by -100% while total assets changed by -5%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-183.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 91% of Healthcare companies in United States.
Cash Cushion Ratio
+36%Cash, after subtracting all debt, equals 36% of its market value (net cash).
Higher than 72% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 93% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 94% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Gain Therapeutics, Inc. made a loss over the last year. Gain Therapeutics, Inc. owes $0.27 for every $1 it owns. Gain Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGain Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.99The share price is 4.99 times Gain Therapeutics, Inc.'s book value per share, higher than 72% of Healthcare companies in United States.
Market cap
$56 MThe total market value of all of Gain Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$11 MWhat Gain Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.26Net worth divided by the number of shares. The share price of $1.29 is 5.0 times this, which is the P/B above.
Return on equity (ROE)
-268.3%Gain Therapeutics, Inc. lost 268.3% of its shareholders' money over the last year, lower than 88% of Healthcare companies in United States.
Owes vs Owns
0.27×Gain Therapeutics, Inc. owes $0.27 for every $1 it owns (low), lower than 64% of Healthcare companies in United States.
Dividend yield
NoneGain Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossGain Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashGain Therapeutics, Inc. held $20 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Gain Therapeutics, Inc.: $56 M ÷ $11 M (30 Jun 2026) = 5.0.
What is Gain Therapeutics, Inc.'s return on equity?
Gain Therapeutics, Inc. lost 268.3% of its shareholders' money over the last year, lower than 88% of Healthcare companies in United States.
How much does Gain Therapeutics, Inc. owe compared with what it owns?
Gain Therapeutics, Inc. owes $0.27 for every $1 it owns (low), lower than 64% of Healthcare companies in United States.
Does Gain Therapeutics, Inc. pay a dividend?
No. Gain Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.